Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

About this update from Verrica Pharmaceuticals Inc.

Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors  WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company’s novel oncolytic peptide, VP-315 (ruxotemitide), in the treatment of basal cell carcinoma (BCC) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, taking place from May 13-16, 2026, in Chicago, Illinois. Patients with BCC frequently present with multiple tumors, and approximately one-third will develop additional primary tumors over their lifetime, highlighting the need for therapies that address diseases such as BCC with multifocal potential. “The peripheral anticancer activity we are observing well beyond the injection site suggests that VP-315 could be exerting an abscopal effect for the treatment of basal cell carcinoma,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Such activity may indicate a broader immune activation within the tumor microenvironment of non-target lesions. If this is demonstrated in further pivotal testing, it could suggest that VP-315 has a unique potential to not only effectively treat primary BCC lesions but could also address the unmet need in patients with more than one lesion. It could also benefit patients with difficult to detect, residual disease that can sometimes be left behind after surgical excision of the tumor,” Dr. Rieger continued. The poster, titled “VP-315 Demonstrates a Potential Abscopal Effect in Untreated Non-Target Basal Cell Carcinoma (BCC) Lesions” will be presented by Noah Rosenberg MD, Verrica’s Chief Medical Officer. Dr. Rosenberg commented “We are excited about the potential of VP-315 to provide a primary and/or neoadjuvant treatment option for patients with BCC, whether it be their first lesion or multiple lesions after a long history of BCC. While the best outcome for patients is to completely eliminate the tumor, which we have observed in many patients in our Phase 2 study, overall tumor size was reduced on average by 86%, which is clinically meaningful. Thi...

View stock analysis, news, and events for Verrica Pharmaceuticals Inc.